
James Lomas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3582422/publications.pdf Version: 2024-02-01



IMMES LOMAS

| and blockerick from cross-country data. Buy Lubba Hearth, 2015, 3, PUDOPA. 8.9 10 2 A Health Opportunity Cost Threshold for Cast Effectiveness Analysis in the United States. Anals of Anals of Anals Co21, 174, 25-32. 8.1 60 3 Using Mobile Health Camification to Facilitate Cognitive Behavioral Therapy Skills Practice in Child Anals Coper Clinical Iral, JMR Service Cames, 2016, 6, e). 8.1 61 4 Resolving the &CocCost.Effective but Unaffordable&C-Paradox: Estimating the Health Opportunity Costs of Normarginal Budget Impacts. Value in Health, 2018, 21, 266-275. 0.3 56 9 Healtheare Cost.Regressions: Coing Beyond the Moan to Estimate the Full Distribution. Health 1.7 52 6 Informing a Cost.Effective but Unaffordable&C-Paradox: Estimating the Mealth Connors. (United Kingdom), 2015, 24, 1192-121. 1.7 52 7 Estimating the Marginal Productivity of the English National Health Service From 2003 to 2012. Value 0.3 42 8 An Educational Review About Using Cost Data for the Purpose of Cost Effectiveness Analysis. 8.3 83 9 Is an ounce of prevention worth a pound of cure? A cross-sectional study of the Impact of English 1.9 23 23 10 APPLYING BETA&CYPE Si2E DISTRIBUTIONS TO HEALTHCARE COST REGRESSIONS. Journal of Applied 2.3 23 23 11 A Quasi Mo | # | Article | IF | CITATIONS |
|--|----|--|-----------------------|-------------------------|
| 2 Internal Medicine, 2021, 174, 25-32. 5.9 It 3 Lising Mobile Health Comfination to Facilitate Cognitive Behavioral Therapy Skills Practice in Child 5.1 6.1 4 Resolving the AceCost-Effective but Unaffordable3c-Paradox: Estimating the Health Opportunity Costs of 0.3 5.1 6 Nonmarginal Budget Impacts. Value in Health, 2018, 21, 266-275. 0.3 5.1 7 Healthcare Cost Regressions: Coing Beyond the Moan to Estimate the Full Distribution. Health 1.7 6.2 6 Informing a Cost-Effective best States of the Maginal Productivity of the English National Health Service From 2003 to 2012. Value 0.3 41 7 Estimating the Marginal Productivity of the English National Health Service From 2003 to 2012. Value 0.3 42 8 An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis. 3.3 33 9 Is an ounce of prevention worth a pound of cure? A cross-sectional study of the impact of English Purmacoceconomics, 2019, 37, 631-643. 1.0 2.3 23 10 APPLYING BETASCTYPE SIZE DISTRIBUTIONS TO HEALTHCARE COST RECRESSIONS. Journal of Applied 2.3 23 11 Heavie Add and Non-moral Bata: an Application to Headrametric Regression Methods for Heavie Add and Non-moral Bata: an Application to Headrametri | 1 | | 4.7 | 181 |
| 3 Analety Treatment: Open Clinical Irial, Milk Serious Games, 2018, 6, e9. 311 31 31 31 4 Resolving the aCoc Cost-Effective but Unaffordable&Grandox: Estimating the Health Opportunity Costs of Nonmarginal Budget Impacts. Value in Health, 2018, 21, 266-275. 0.3 58 5 Healthcare Cost. Represente: Coing Beyond the Mean to Estimate the Foll Distribution. Health 1.7 52 6 Informing a Cost.Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach. Pharmacoeconomics, 2020, 38, 1319-1331. 3.8 44 7 Estimating the Marginal Productivity of the English National Health Service From 2003 to 2012. Value in Health, 2019, 22, 95-1002. 0.3 42 8 An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis. 8.3 33 9 Is an onnee of prevention worth a pound of cure? A cross sectional study of the Impact of English public health grant on mortality and morbidity. BMI Open, 2020. 10, e036411. 1.9 2.3 23 10 APPLYINC BETAGETYPE SIZE DISTRIBUTIONS TO HEALTHCARE COST REORESSIONS. Journal of Applied Econometrics, 2014, 29, 649-670. 1.1 22 11 Assessment, Value in Health, 2019, 22, 898-905. 1.2 1.1 22 12 Identification in all-cause and disease specific models of mortality. | 2 | | 3.9 | 103 |
| Image: A set of the set | 3 | | 3.1 | 65 |
| Connemics (United Kingdom), 2015, 24, 1192-1212. 1.0 1.1 Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal 3.3 44 Productivity Approach. Pharmacoeconomics, 2020, 38, 1319-1331. 3.3 44 Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal 3.3 44 Informating the Marginal Productivity of the English National Health Service From 2003 to 2012. Value 0.3 44 In Health, 2019, 22, 995-1002. 0.3 44 In Health, 2019, 27, 631-643. 3.3 33 Is an ounce of prevention worth a pound of cure? A cross-sectional study of the impact of English 1.9 24 In APPLYING BETAGETYPE SIZE DISTRIBUTIONS TO HEALTHCARE COST REGRESSIONS. Journal of Applied 2.3 23 In A Quest-Monte-Carlo Comparison of Parametric and Semiparametric Regression Methods for Heavytalied and Non-normal Data: an Application to Healthcare Costs. Journal of the Royal Statistical 1.1 24 In Impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all-cause and disease specific models of mortality. Health Economics (United) TJ ETQq0 0 orgBT /Ouzrlock 104 14 In Corporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment. Value in Health, 2019, 22, 898-905. 23 23 <td>4</td> <td></td> <td>0.3</td> <td>58</td> | 4 | | 0.3 | 58 |
| 9 Productivity Approach. Pharmacoeconomics, 2020, 38, 1319-1331. 33 44 7 Estimating the Marginal Productivity of the English National Health Service From 2003 to 2012. Value 0.3 45 8 An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis. 9.3 38 9 Is an ounce of prevention worth a pound of cure? A cross-sectional study of the impact of English public health grant on mortality and morbidity. BMI Open, 2020, 10, e036411. 1.0 28 10 APPLYING BETAAGTYPE SIZE DISTRIBUTIONS TO HEALTHCARE COST REGRESSIONS. Journal of Applied Econometrics, 2014, 29, 649-670. 2.3 27 11 AppLyING BETAAGTYPE SIZE DISTRIBUTIONS TO HEALTHCARE COST REGRESSIONS. Journal of Applied Econometrics, 2014, 29, 649-670. 1.1 28 12 A Quasi-Monte-Carlo Comparison of Parametric and Semiparametric Regression Methods for Heavytalled and Non-normal Data: an Application to Healthcare Costs. Journal of the Royal Statistical 1.1 28 13 Incorporating Affordability Concerns Within Cost: Effectiveness Analysis for Health Technology 0.3 21 14 Accounting for Timing when Assessing Health-Related Policies. Journal of Benefit-Cost Analysis, 2019, 1.2 17 13 Accounting for Timing when Assessing Health-Related Policies. Journal of Benefit-Cost Analysis, 2019, 1.2 17 14 Acco | 5 | Healthcare Cost Regressions: Going Beyond the Mean to Estimate the Full Distribution. Health Economics (United Kingdom), 2015, 24, 1192-1212. | 1.7 | 52 |
| 1 In Health, 2019, 22, 995-1002. 0.3 41 8 An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis. 3.3 33 9 pt S an ounce of prevention worth a pound of cure? A cross-sectional study of the impact of English public health grant on mortality and morbidity. BM Open, 2020, 10, e036411. 1.9 24 10 APPLYING BETA%CTYPE SIZE DISTRIBUTIONS TO HEALTHCARE COST REGRESSIONS, Journal of Applied Econometrics, 2014, 29, 649-670. 2.3 27 11 Heavy-tailed and Non-normal Data: an Application to Healthcare Costs, Journal of the Royal Statistical Society Series A: Statistics in Society, 2016, 179, 951-974. 1.1 22 12 Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology 0.3 21 13 Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology 0.3 21 14 Accounting for Timing when Assessing Health-Related Policies, Journal of Benefit-Cost Analysis, 2019, 1.2 17 15 Valuing health outcomes: developing better defaults based on health opportunity costs. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 229-736. 1.4 10 14 Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research. Clinical Therapeutics, 2020, 42, 44-59.e2. 2.5 <td>6</td> <td>Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach. Pharmacoeconomics, 2020, 38, 1319-1331.</td> <td>3.3</td> <td>48</td> | 6 | Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach. Pharmacoeconomics, 2020, 38, 1319-1331. | 3.3 | 48 |
| 9 Pharmacoeconomics, 2019, 37, 631-643. 3.3 <td>7</td> <td></td> <td>0.3</td> <td>45</td> | 7 | | 0.3 | 45 |
| 9 public health grant on mortality and morbidity. BMJ Open, 2020, 10, e036411. 1.9 2.4 10 APPLYINC BETAäGYPE SIZE DISTRIBUTIONS TO HEALTHCARE COST REGRESSIONS. Journal of Applied Econometrics, 2014, 29, 649-670. 2.3 27 11 Heavy-tailed and Non-normal Data: an Application to Healthcare Costs. Journal of the Royal Statistical Society Series A: Statistics in Society, 2016, 179, 951-974. 1.1 22 12 The impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all-cause and disease specific models of mortality. Health Economics (United) Tj ETQq0 0 0 rgBT /Owerlock 10:4 10:4 13 Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment. Value in Health, 2019, 22, 898-905. 0.3 21 14 Accounting for Timing when Assessing Health-Related Policies. Journal of Benefit-Cost Analysis, 2019, 10, 73-105. 1.2 17 15 Valuing health outcomes: developing better defaults based on health opportunity costs. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 729-736. 1.4 10 16 Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research. Clinical Therapeutics, 2020, 42, 44-59, e2. 2.5 10 17 How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13. Applied Health Econo | 8 | | 3.3 | 33 |
| 10 Econometrics, 2014, 29, 649-670. 2.3 2.1 11 AQuasi-Monte-Carlo Comparison of Parametric and Semiparametric Regression Methods for 1.1 2.3 2.1 11 Heavy-tailed and Non-normal Data: an Application to Healthcare Costs. Journal of the Royal Statistical 1.1 2.5 12 The impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all-cause and disease specific models of mortality. Health Economics (United) Tj ETQq0 0 0 rgBT /Owerlock 10:4 13 Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology 0.3 21 14 Accounting for Timing when Assessing Health-Related Policies. Journal of Benefit-Cost Analysis, 2019, 1.2 1.7 15 Valuing health outcomes: developing better defaults based on health opportunity costs. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 729-736. 1.4 1.6 16 Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research. Clinical Therapeutics, 2020, 42, 44-59.e2. 2.5 1.6 17 How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13. Applied Health Economics and Health Policy, 2021, 19, 885-903. 2.1 1.6 18 Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare Sys | 9 | | 1.9 | 28 |
| 11 Heavy-tailed and Non-normal Data: an Application to Healthcare Costs. Journal of the Royal Statistical 1.1 24 12 Society Series A: Statistics in Society, 2016, 179, 951-974. The impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all-cause and disease specific models of mortality. Health Economics (United) Tj ETQq0 0 0 rgBT /Owarlock 10:4 13 Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology 0.3 21 14 Accounting for Timing when Assessing Health-Related Policies. Journal of Benefit-Cost Analysis, 2019, 10, 73-105. 1.2 17 15 Valuing health outcomes: developing better defaults based on health opportunity costs. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 729-736. 1.4 16 16 Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research. Clinical Therapeutics, 2020, 42, 44-59.e2. 2.1 16 17 How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13. Applied Health Economics and Health Policy, 2021, 19, 885-903. 2.1 16 18 Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological 2.0 2.1 16 | 10 | | 2.3 | 27 |
| 12 identification in all-cause and disease specific models of mortality. Health Economics (United) Tj ETQq0 0 0 rgBT /Owerlock 1043 13 Incorporating Affordability Concerns Within Cost-Effectiveness Analysis for Health Technology Assessment. Value in Health, 2019, 22, 898-905. 0.3 21 14 Accounting for Timing when Assessing Health-Related Policies. Journal of Benefit-Cost Analysis, 2019, 10, 73-105. 1.2 17 15 Valuing health outcomes: developing better defaults based on health opportunity costs. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 729-736. 1.4 16 16 Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research. Clinical Therapeutics, 2020, 42, 44-59.e2. 2.5 16 17 How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13. Applied Health Economics and Health Policy, 2021, 19, 885-903. 2.1 16 18 Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological 2.8 16 | 11 | Heavy-tailed and Non-normal Data: an Application to Healthcare Costs. Journal of the Royal Statistical | 1.1 | 25 |
| 13 Assessment. Value in Health, 2019, 22, 898-905. 0.3 21 14 Accounting for Timing when Assessing Health-Related Policies. Journal of Benefit-Cost Analysis, 2019, 10, 73-105. 1.2 17 15 Valuing health outcomes: developing better defaults based on health opportunity costs. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 729-736. 1.4 16 16 Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research. Clinical Therapeutics, 2020, 42, 44-59.e2. 2.5 16 17 How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13. Applied Health Economics and Health Policy, 2021, 19, 885-903. 2.1 16 18 Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological 3.3 14 | 12 | The impact of NHS expenditure on health outcomes in England: Alternative approaches to identification in all-cause and disease specific models of mortality. Health Economics (United) Tj ETQq0 0 0 rgB | T /O v.e rloch | a 1 024 f 50 297 |
| 14 10, 73-105. 1.2 17 15 Valuing health outcomes: developing better defaults based on health opportunity costs. Expert 1.4 16 15 Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial 2.5 16 16 Reflective is Marginal Healthcare Research. Clinical Therapeutics, 2020, 42, 44-59.e2. 2.5 16 17 How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13. 2.1 16 18 Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological 2.8 16 | 13 | | 0.3 | 21 |
| 13 Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 729-736. 1.4 16 16 Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research. Clinical Therapeutics, 2020, 42, 44-59.e2. 2.5 16 17 How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13. Applied Health Economics and Health Policy, 2021, 19, 885-903. 2.1 16 18 Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological 2.2 16 | 14 | | 1.2 | 17 |
| 16 Estimates and the Need for Further Research. Clinical Therapeutics, 2020, 42, 44-59.e2. 2.5 16 17 How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13. Applied Health Economics and Health Policy, 2021, 19, 885-903. 2.1 16 18 Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological 2.2 16 | 15 | Valuing health outcomes: developing better defaults based on health opportunity costs. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 729-736. | 1.4 | 16 |
| 17 Applied Health Economics and Health Policy, 2021, 19, 885-903. 2.1 16 18 Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological 2.2 16 | 16 | Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research. Clinical Therapeutics, 2020, 42, 44-59.e2. | 2.5 | 16 |
| | 17 | | 2.1 | 16 |
| | 18 | | 3.3 | 16 |

James Lomas

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries. BMJ Global Health, 2020, 5, e003006. | 4.7 | 14 |
| 20 | A pharmacoeconomic approach to assessing the costs and benefits of air quality interventions that improve health: a case study. BMJ Open, 2016, 6, e010686. | 1.9 | 12 |
| 21 | Economic Evaluation of Environmental Interventions: Reflections on Methodological Challenges and Developments. International Journal of Environmental Research and Public Health, 2018, 15, 2459. | 2.6 | 12 |
| 22 | Causal impact of social care, public health and healthcare expenditure on mortality in England: cross-sectional evidence for 2013/2014. BMJ Open, 2021, 11, e046417. | 1.9 | 11 |
| 23 | Cured Today, Ill Tomorrow: A Method for Including Future Unrelated Medical Costs in Economic Evaluation in England and Wales. Value in Health, 2020, 23, 1027-1033. | 0.3 | 10 |
| 24 | Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment. Applied Health Economics and Health Policy, 2021, , 1. | 2.1 | 10 |
| 25 | Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations. Pharmacoeconomics, 2020, 38, 665-681. | 3.3 | 9 |
| 26 | Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries. Health Policy and Planning, 2022, 37, 45-54. | 2.7 | 8 |
| 27 | The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence. Pharmacoeconomics, 2016, 34, 901-912. | 3.3 | 7 |
| 28 | Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease. PharmacoEconomics - Open, 2018, 2, 403-413. | 1.8 | 7 |
| 29 | Does public longâ€ŧerm care expenditure improve careâ€related quality of life of service users in England?. Health Economics (United Kingdom), 2021, 30, 2561-2581. | 1.7 | 5 |
| 30 | How Responsive is Mortality to Locally Administered Healthcare Expenditure? Estimates for England for 2014/15. Applied Health Economics and Health Policy, 2022, 20, 557-572. | 2.1 | 5 |
| 31 | Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence. Pharmacoeconomics, 2016, 34, 981-992. | 3.3 | 4 |
| 32 | The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS. Pharmacoeconomics, 2022, 40, 233-239. | 3.3 | 4 |
| 33 | Assessing the Impact of Health Care Expenditures on Mortality Using Cross-Country Data. World Scientific Series in Global Healthcare Economics and Public Policy, 2020, , 3-49. | 0.1 | 3 |
| 34 | Health Inequalities: To What Extent are Decision-Makers and Economic Evaluations on the Same Page? An English Case Study. Applied Health Economics and Health Policy, 2022, 20, 793-802. | 2.1 | 3 |